Clinical features and cancer risk in families with pathogenic <i>CDH1</i> variants irrespective of clinical criteria.

Abstract

The clinical phenotype of <i>CDH1</i> pathogenic variant carriers has mostly been studied in families that fulfil criteria of hereditary diffuse gastric cancer (HDGC). We aimed at determining cancer phenotype and cancer risk estimation among families with <i>CDH1</i> pathogenic variants not selected by HDGC clinical criteria. Patients were all consecutively identified <i>CDH1</i> pathogenic variant carriers from a clinical laboratory tested with multigene panel testing and from an academic cancer genetics programme. Clinical and demographic features, cancer phenotypes and genotype-phenotype correlations were determined among <i>CDH1</i> families. Age-specific cumulative cancer risks (penetrance) were calculated based on 38 families with available pedigrees. Within the 113 <i>CDH1</i> pathogenic variant probands and 476 relatives, 113 had gastric cancer, 177 breast cancer and 196 other cancers. Mean age at diagnosis was 47 for gastric and 54 for breast cancer. Forty-six per cent fulfilled criteria of HDGC. While 36% of families had both gastric and breast cancers, 36% had breast but no gastric cancers and 16% had gastric but not breast cancers. Cumulative risk of cancer by age 80 was 37.2% for gastric and 42.9% for breast cancer. In unselected <i>CDH1</i> pathogenic variant carrier families, gastric cancer risks were lower and age at diagnosis higher than previously reported in families pre-selected for HDGC criteria. A substantial proportion of families did not present with any gastric cancers and their cancers were limited to breast. Thus, clinical criteria for <i>CDH1</i> testing should be widened, including breast cancer families only, and a consideration for delayed prophylactic gastrectomy/surveillance should be evaluated.